Tekla Life Sciences Investors (HQL) stock price

Tekla Life Sciences Investors (HQL) is a Financial Services · Asset Management company listed on NYSE. Price $19.39 (-0.92%), Market cap $0.54B, P/E ratio 6.33, 52-week low–high $12.17 ~ $18.22.

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management,

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Tekla Life Sciences Investors are updated in real time on BlackAll Trade.

Tekla Life Sciences Investors financial summary

Key ratios · profitability · growth

Frequently asked questions

What is the current Tekla Life Sciences Investors (HQL) stock price?

Tekla Life Sciences Investors trades at $19.39 (-0.92%). Real-time quotes and charts are available on BlackAll Trade.

What is the Tekla Life Sciences Investors (HQL) market cap?

Tekla Life Sciences Investors has a market cap of about $0.54B. Its P/E ratio is 6.33.

What does Tekla Life Sciences Investors (HQL) do?

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of compan